SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases
(2009) Haematologica : the hematology journal — Vol. 94, n° 4, p. 576-580 (2009)
Files
576.pdf
Open Access - Adobe PDF
- 347.53 KB
Details
- Authors
- Abstract
- JAK2 V617F, identified in the majority of patients with myeloproliferative neoplasms, tyrosine phosphorylates SOCS3 and escapes its inhibition. Here, we demonstrate that the JAK2 exon 12 mutants described in a subset of V617F-negative MPN cases, also stabilize tyrosine phosphorylated SOCS3. SOCS3 tyrosine phosphorylation was also observed in peripheral blood mononuclear cells and granulocytes isolated from patients with JAK2 H538QK539L or JAY2 F537-K539delinsL mutations. JAK kinase inhibitors, which effectively inhibited the proliferation of cells expressing V617F or K539L, also caused a dose-dependent reduction in both mutant JAK2 and SOCS3 tyrosine phosphorylation. We propose, therefore, that SOCS3 tyrosine phosphorylation may be a novel bio-marker of myeloproliferative neoplasms resulting from a JAK2 mutation and a potential reporter of effective JAK2 inhibitor therapy currently in clinical development.
- Affiliations
Citations
Elliott, J., Suessmuth, Y., Scott, L. M., Nahlik, K., McMullin, M. F., Constantinescu, S., Green, A. R., & Johnston, J. A. (2009). SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica : the hematology journal, 94(4), 576-580. https://doi.org/10.3324/haematol.2008.002352 (Original work published 2009)